154 related articles for article (PubMed ID: 8433467)
21. Cyst fluid CA 125 levels in ovarian epithelial neoplasms.
Menczer J; Ben-Baruch G; Moran O; Lipitz S
Obstet Gynecol; 1993 Jan; 81(1):25-8. PubMed ID: 8416456
[TBL] [Abstract][Full Text] [Related]
22. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
23. C-reactive protein concentrations and subsequent ovarian cancer risk.
McSorley MA; Alberg AJ; Allen DS; Allen NE; Brinton LA; Dorgan JF; Pollak M; Tao Y; Helzlsouer KJ
Obstet Gynecol; 2007 Apr; 109(4):933-41. PubMed ID: 17400857
[TBL] [Abstract][Full Text] [Related]
24. Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Annicchiarico C; Prato B; Bianchi R; Fioretti P
Tumour Biol; 1992; 13(5-6):287-93. PubMed ID: 1290026
[TBL] [Abstract][Full Text] [Related]
25. Sources of variability in normal CA 125 levels.
Westhoff C; Levin B; Ladd G; O'Connor J
Cancer Epidemiol Biomarkers Prev; 1992; 1(5):357-9. PubMed ID: 1305467
[TBL] [Abstract][Full Text] [Related]
26. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year.
Low RN; Duggan B; Barone RM; Saleh F; Song SY
Radiology; 2005 Jun; 235(3):918-26. PubMed ID: 15914479
[TBL] [Abstract][Full Text] [Related]
27. Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.
Cane P; Azen C; Lopez E; Platt LD; Karlan BY
Gynecol Oncol; 1995 May; 57(2):240-5. PubMed ID: 7729742
[TBL] [Abstract][Full Text] [Related]
28. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer.
Zurawski VR; Sjovall K; Schoenfeld DA; Broderick SF; Hall P; Bast RC; Eklund G; Mattsson B; Connor RJ; Prorok PC
Gynecol Oncol; 1990 Mar; 36(3):299-305. PubMed ID: 2318438
[TBL] [Abstract][Full Text] [Related]
29. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
30. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
Chen DX; Schwartz PE; Li FQ
Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Reiter W; Pahl H; Fateh-Moghadam A
Int J Cancer; 1996 Aug; 69(4):329-34. PubMed ID: 8797878
[TBL] [Abstract][Full Text] [Related]
32. Ovarian cancer screening.
Kurjak A; Predanic M
Curr Opin Obstet Gynecol; 1994 Feb; 6(1):67-74. PubMed ID: 8180353
[TBL] [Abstract][Full Text] [Related]
33. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):3-7. PubMed ID: 8482556
[TBL] [Abstract][Full Text] [Related]
34. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
35. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
36. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
[TBL] [Abstract][Full Text] [Related]
37. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study.
Jacobs IJ; Skates S; Davies AP; Woolas RP; Jeyerajah A; Weidemann P; Sibley K; Oram DH
BMJ; 1996 Nov; 313(7069):1355-8. PubMed ID: 8956699
[TBL] [Abstract][Full Text] [Related]
38. [The value of CA 125 determination in the serum of patients with ovarian cancer].
Bartel U; Johannsen B; Elling D
Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
[TBL] [Abstract][Full Text] [Related]
39. Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women.
Arslan AA; Zeleniuch-Jacquotte A; Lundin E; Micheli A; Lukanova A; Afanasyeva Y; Lenner P; Krogh V; Muti P; Rinaldi S; Kaaks R; Berrino F; Hallmans G; Toniolo P
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1531-5. PubMed ID: 14693749
[TBL] [Abstract][Full Text] [Related]
40. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers.
Kramer BS; Gohagan J; Prorok PC; Smart C
Cancer; 1993 Jan; 71(2 Suppl):589-93. PubMed ID: 8420681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
